1.3. Antisecretory drugs and mucosal protectants
1.3.1. H2-receptor antogonists
1.3.2. Selective antimuscarinics
1.3.3. Chelates and complexes
Prescribing Notes:
The UK licenced product is the 1g/5ml sugar free oral suspension.
The tablets are not a licensed product in the UK.
1.3.4. Prostaglandin analogues
1.3.5. Proton pump inhibitors
Patients should be maintained on the lowest dose possible. Those with GORD without oesophagitis are encouraged to use PPIs "on demand". Measurement of serum-magnesium concentrations should be considered before and during prolonged treatment with a proton pump inhibitor, especially when used with other drugs that cause hypomagnesaemia or with digoxin.Prescribing Notes:
Patients should be maintained on the lowest dose possible. Those with GORD without oesophagitis are encouraged to use lansoprazole 'on demand'.
Prescribing Notes:
Patients should be maintained on the lowest dose possible. Those with GORD without oesophagitis are encouraged to use omeprazole 'on demand'.
Restrictions:
Restricted for specialist initiation in patients with narrow-bore feeding tubes.
Prescribing Notes:
Lansoprazole orodispersible tablets are the preferred formulation in NHSGGC when administration via enteral tube is required. Good technique is important to avoid tube blockages. For advice on administering lansoprazole (branded or generic) via enteral feeding tubes please click here.
Restrictions:
Use is restricted to patients in the immediate period (2 weeks) after bariatric surgery.
Prescribing Notes:
- The dispersible preparations are considerably more expensive than omeprazole capsules and should not be used unless necessary.
- Omeprazole MUPS are not licensed for enteral feeding tube administration and appear to be associated with an increased risk of tube blockages. In contrast, lansoprazole orodispersible tablets are licensed and are the preferred formulation in NHSGGC for this route of administration.